Viking Therapeutics’ collaboration with Ligand Pharmaceuticals has sailed into some trouble, with one of the partners keen to ...
Ligand Pharmaceuticals has accused Viking Therapeutics of breaching obligations under their licensing deal for thyroid hormone receptor beta (TRβ) therapies and moved to terminate the program. Viking ...
Q1 2026. Management View. Brian Lian said the quarter’s operational focus was advancing VK2735 across multiple Phase III-enabl ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results